n,n-dimethyltryptamine has been researched along with Multiple Sclerosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bazylewicz, M; Chorąży, M; Collins, F; Czarnowska, A; Gudowska-Sawczuk, M; Kapica-Topczewska, K; Kochanowicz, J; Kulczyńska-Przybik, A; Kulikowska, J; Kułakowska, A; Mroczko, B | 1 |
| Baumann, M; Berger, T; Breu, M; Kornek, B; Lechner, C; Schneider, L; Seidl, R; Siegert, S; Tobudic, S; Winkler, S | 1 |
| Brown, JS; Geiger, C; Jessop, N; Jin, H; Muros-Le Rouzic, E; Pedotti, R; Raposo, C; Whitley, L | 1 |
3 other study(ies) available for n,n-dimethyltryptamine and Multiple Sclerosis
| Article | Year |
|---|---|
Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies.
Topics: Antibodies, Viral; COVID-19; Dimethyl Fumarate; Glatiramer Acetate; Humans; Immunoglobulin A; Immunoglobulin G; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; N,N-Dimethyltryptamine; SARS-CoV-2 | 2023 |
Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis.
Topics: Adolescent; Antibodies, Viral; Child; Child, Preschool; COVID-19; COVID-19 Vaccines; Humans; Immunity, Humoral; Multiple Sclerosis; N,N-Dimethyltryptamine; Retrospective Studies; RNA, Messenger; SARS-CoV-2; Vaccination | 2023 |
Anti-SARS-CoV-2 monoclonal antibodies for the treatment of mild-to-moderate COVID-19 in multiple sclerosis: A retrospective cohort study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Viral; COVID-19; Female; Humans; Male; Middle Aged; Multiple Sclerosis; N,N-Dimethyltryptamine; Retrospective Studies; SARS-CoV-2 | 2023 |